Several recent studies have adopted the approach to use CD127, CD25, and FOXP3 for the quantification of Treg cells in tumor-bearing individuals and could demonstrate increased numbers of CD4+CD25highCD127low Treg cells in patients with solid tumors [7–10] and hematologic malignancies [11–13]. This evidence concerns the gene IL2RA and hematologic disorder.